SCN5A Variant S11R
Summary of observed carriers, functional annotations, and structural context for SCN5A S11R. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
5%
0/11 effective observations
Estimated BrS1 penetrance
5%
0/11 effective observations
Total carriers
1
0 BrS1 · 0 LQT3 · 1 unaffected
Variant features alone are equivalent to phenotyping 0 individuals for Brugada syndrome and 0 individuals for LQT3.
In silico predictors
| PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
|---|---|---|---|---|---|
| -1.51 | 0.201 | -2.58 | 0.296 | 0 | 6 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
| Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
|---|---|---|---|---|---|---|---|
| Literature, cohort, and gnomAD | – | 1 | 1 | 0 | 0 | – | |
| Variant features alone | – | 15 | 15 | 0 | 0 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
| Neighbour residue | Distance (Å) | Observed variants |
|---|---|---|
| 1 | 12 | c.-53+1G>A, M1I, |
| 2 | 11 | A2T, |
| 3 | 11 | N3K, N3K, N3S, |
| 4 | 10 | F4V |
| 5 | 9 | |
| 6 | 8 | L6S, |
| 7 | 8 | P7L, P7R, |
| 8 | 7 | R8W, R8P, R8Q, |
| 9 | 5 | G9S, G9V, |
| 10 | 4 | T10S, T10S, |
| 11 | 0 | S11R, S11R, S11R, |
| 12 | 4 | |
| 13 | 5 | |
| 14 | 7 | R14S, R14H, R14C, |
| 15 | 8 | R15M, R15T, R15G, |
| 16 | 8 | F16L, F16L, F16L, |
| 17 | 9 | |
| 18 | 10 | R18Q, R18W, |
| 19 | 11 | |
| 20 | 11 | S20F, |
| 21 | 12 | L21V, |
| 22 | 13 | A22V, |
| 23 | 13 | A23S, |
| 24 | 14 | |
| 25 | 14 | E25K, |
| 26 | 15 |